CS257277B2 - Production method of diphosphone acid derivatives - Google Patents
Production method of diphosphone acid derivatives Download PDFInfo
- Publication number
- CS257277B2 CS257277B2 CS855580A CS558085A CS257277B2 CS 257277 B2 CS257277 B2 CS 257277B2 CS 855580 A CS855580 A CS 855580A CS 558085 A CS558085 A CS 558085A CS 257277 B2 CS257277 B2 CS 257277B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- diphosphonic acid
- acid
- residue
- alkyl
- hydroxy
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000002253 acid Substances 0.000 title description 9
- -1 1,2,4-triazole radical Chemical class 0.000 claims abstract description 36
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims abstract description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 125000002252 acyl group Chemical group 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 150000002367 halogens Chemical group 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims abstract description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract description 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 10
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical class OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 150000002440 hydroxy compounds Chemical class 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical group [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- IVFGIXMLURJXBZ-UHFFFAOYSA-N 1-phosphonopropylphosphonic acid Chemical compound CCC(P(O)(O)=O)P(O)(O)=O IVFGIXMLURJXBZ-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 150000005690 diesters Chemical class 0.000 description 4
- IRYOZLKMXHUGKP-UHFFFAOYSA-N 1-phosphonopentylphosphonic acid Chemical compound CCCCC(P(O)(O)=O)P(O)(O)=O IRYOZLKMXHUGKP-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 2
- OWWOMIFQTFZNGK-UHFFFAOYSA-N 1-phosphonobutylphosphonic acid Chemical compound CCCC(P(O)(O)=O)P(O)(O)=O OWWOMIFQTFZNGK-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229920006158 high molecular weight polymer Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- AUBVNSHIGBWECH-UHFFFAOYSA-N 3-(1,2,4-triazol-1-yl)butanoic acid Chemical compound OC(=O)CC(C)N1C=NC=N1 AUBVNSHIGBWECH-UHFFFAOYSA-N 0.000 description 1
- KIJGYTNIFKJHJQ-UHFFFAOYSA-N 3-(1,2,4-triazol-1-yl)propanoic acid Chemical compound OC(=O)CCN1C=NC=N1 KIJGYTNIFKJHJQ-UHFFFAOYSA-N 0.000 description 1
- JOPDKZAQPYQADQ-UHFFFAOYSA-N 3-(1-ethyltriazol-4-yl)propanoic acid Chemical compound CCN1C=C(CCC(O)=O)N=N1 JOPDKZAQPYQADQ-UHFFFAOYSA-N 0.000 description 1
- TWNQWBBLAMCLMM-UHFFFAOYSA-N 3-(1-methyltriazol-4-yl)propanoic acid Chemical compound CN1C=C(CCC(O)=O)N=N1 TWNQWBBLAMCLMM-UHFFFAOYSA-N 0.000 description 1
- YUEMXJRPUGSFBF-UHFFFAOYSA-N 3-(1h-imidazol-5-yl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCC1=CNC=N1 YUEMXJRPUGSFBF-UHFFFAOYSA-N 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- GRRDNOPINFTOHQ-UHFFFAOYSA-N 5-(1-methyltriazol-4-yl)pentanoic acid Chemical compound CN1C=C(CCCCC(O)=O)N=N1 GRRDNOPINFTOHQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000034970 Heterotopic Ossification Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- BIXHWSYQYONFDQ-UHFFFAOYSA-N N1=C(NC2=C1C=CC=C2)CCC(P(O)(=O)O)(P(O)(=O)O)O.N2=C(NC1=C2C=CC=C1)CCC(=O)O Chemical compound N1=C(NC2=C1C=CC=C2)CCC(P(O)(=O)O)(P(O)(=O)O)O.N2=C(NC1=C2C=CC=C1)CCC(=O)O BIXHWSYQYONFDQ-UHFFFAOYSA-N 0.000 description 1
- QOITYLXTDAAHST-UHFFFAOYSA-N NC=1SC(=C(N1)C)CCCC(P(O)(=O)O)(P(O)(=O)O)O.NC=1SC(=C(N1)C)CCC(P(O)(=O)O)(P(O)(=O)O)O Chemical compound NC=1SC(=C(N1)C)CCCC(P(O)(=O)O)(P(O)(=O)O)O.NC=1SC(=C(N1)C)CCC(P(O)(=O)O)(P(O)(=O)O)O QOITYLXTDAAHST-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- ZDRXYXXAPJIXCQ-UHFFFAOYSA-N OC(CCC1=NC=CC=C1)(P(O)(=O)O)P(O)(=O)O.N1=C(C=CC=C1)CCC(=O)O Chemical compound OC(CCC1=NC=CC=C1)(P(O)(=O)O)P(O)(=O)O.N1=C(C=CC=C1)CCC(=O)O ZDRXYXXAPJIXCQ-UHFFFAOYSA-N 0.000 description 1
- NPGCRIMYSGBCDU-UHFFFAOYSA-N OC(CCC=1C=NC=CC1)(P(O)(=O)O)P(O)(=O)O.N1=CC(=CC=C1)CCC(=O)O Chemical compound OC(CCC=1C=NC=CC1)(P(O)(=O)O)P(O)(=O)O.N1=CC(=CC=C1)CCC(=O)O NPGCRIMYSGBCDU-UHFFFAOYSA-N 0.000 description 1
- HAUNODKIOGRZIF-UHFFFAOYSA-N OC(CCCCN1N=CN=C1)(P(O)(=O)O)P(O)(=O)O.N1(N=CN=C1)CCCCC(=O)O Chemical compound OC(CCCCN1N=CN=C1)(P(O)(=O)O)P(O)(=O)O.N1(N=CN=C1)CCCCC(=O)O HAUNODKIOGRZIF-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UNNAKYSEBJLOTH-UHFFFAOYSA-N [1-acetamido-3-(1h-imidazol-5-yl)-1-phosphonopropyl]phosphonic acid Chemical compound CC(=O)NC(P(O)(O)=O)(P(O)(O)=O)CCC1=CNC=N1 UNNAKYSEBJLOTH-UHFFFAOYSA-N 0.000 description 1
- SVUQBVWLXYSYMG-UHFFFAOYSA-N [1-acetyloxy-3-(1h-imidazol-5-yl)-1-phosphonopropyl]phosphonic acid Chemical compound CC(=O)OC(P(O)(O)=O)(P(O)(O)=O)CCC1=CNC=N1 SVUQBVWLXYSYMG-UHFFFAOYSA-N 0.000 description 1
- WHVCUDZMIYUPAF-UHFFFAOYSA-N [1-amino-3-(1h-imidazol-5-yl)-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(N)CCC1=CNC=N1 WHVCUDZMIYUPAF-UHFFFAOYSA-N 0.000 description 1
- ZQPFHJWTDCDLOP-UHFFFAOYSA-N [1-hydroxy-1-phosphono-3-(1,3-thiazol-2-yl)propyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCC1=NC=CS1 ZQPFHJWTDCDLOP-UHFFFAOYSA-N 0.000 description 1
- JSQKBPJHAOTJFO-UHFFFAOYSA-N [1-hydroxy-1-phosphono-3-(1,3-thiazol-4-yl)propyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCC1=CSC=N1 JSQKBPJHAOTJFO-UHFFFAOYSA-N 0.000 description 1
- PYJRWIXWDIKLGE-UHFFFAOYSA-N [1-hydroxy-1-phosphono-3-(1,3-thiazol-5-yl)propyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCC1=CN=CS1 PYJRWIXWDIKLGE-UHFFFAOYSA-N 0.000 description 1
- ASVHJTDUWDLKST-UHFFFAOYSA-N [1-hydroxy-1-phosphono-3-(1h-1,2,4-triazol-5-yl)propyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCC=1N=CNN=1 ASVHJTDUWDLKST-UHFFFAOYSA-N 0.000 description 1
- HEGDQYHMVILILH-UHFFFAOYSA-N [1-hydroxy-1-phosphono-3-(triazol-1-yl)propyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCN1C=CN=N1 HEGDQYHMVILILH-UHFFFAOYSA-N 0.000 description 1
- GZVPCQQYZIXTKF-UHFFFAOYSA-N [1-hydroxy-1-phosphono-4-(1,3,5-trimethyl-2-oxoimidazolidin-4-yl)butyl]phosphonic acid Chemical compound CC1C(CCCC(O)(P(O)(O)=O)P(O)(O)=O)N(C)C(=O)N1C GZVPCQQYZIXTKF-UHFFFAOYSA-N 0.000 description 1
- ARUQLVAQVOCENV-UHFFFAOYSA-N [1-hydroxy-1-phosphono-4-(2h-triazol-4-yl)butyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCCC1=CNN=N1 ARUQLVAQVOCENV-UHFFFAOYSA-N 0.000 description 1
- CXJKFNJDDDGKKJ-UHFFFAOYSA-N [1-hydroxy-1-phosphono-4-(triazol-2-yl)butyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCCN1N=CC=N1 CXJKFNJDDDGKKJ-UHFFFAOYSA-N 0.000 description 1
- RPJIYGDGCJUXGW-UHFFFAOYSA-N [1-hydroxy-1-phosphono-5-(1h-1,2,4-triazol-5-yl)pentyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCCCC=1N=CNN=1 RPJIYGDGCJUXGW-UHFFFAOYSA-N 0.000 description 1
- ZMFLALKAHHMIHU-UHFFFAOYSA-N [1-hydroxy-1-phosphono-5-(2h-triazol-4-yl)pentyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCCCC1=CNN=N1 ZMFLALKAHHMIHU-UHFFFAOYSA-N 0.000 description 1
- GRBAKABPUBUZEC-UHFFFAOYSA-N [1-hydroxy-1-phosphono-5-(triazol-1-yl)pentyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCCCN1C=CN=N1 GRBAKABPUBUZEC-UHFFFAOYSA-N 0.000 description 1
- KJSSILJKCHUCKN-UHFFFAOYSA-N [1-hydroxy-3-(1-methylbenzimidazol-2-yl)-1-phosphonopropyl]phosphonic acid Chemical compound C1=CC=C2N(C)C(CCC(O)(P(O)(O)=O)P(O)(O)=O)=NC2=C1 KJSSILJKCHUCKN-UHFFFAOYSA-N 0.000 description 1
- JTHOGGRCTXHEGM-UHFFFAOYSA-N [1-hydroxy-3-(1h-imidazol-2-yl)-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCC1=NC=CN1 JTHOGGRCTXHEGM-UHFFFAOYSA-N 0.000 description 1
- OCVITJZAQBIHLG-UHFFFAOYSA-N [1-hydroxy-3-(1h-imidazol-5-yl)-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCC1=CNC=N1 OCVITJZAQBIHLG-UHFFFAOYSA-N 0.000 description 1
- ULQIPUBXZDXHFB-UHFFFAOYSA-N [1-hydroxy-3-(2-methyl-1,3-oxazol-4-yl)-1-phosphonopropyl]phosphonic acid Chemical compound CC1=NC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=CO1 ULQIPUBXZDXHFB-UHFFFAOYSA-N 0.000 description 1
- WFFDAVXCSRTNQZ-UHFFFAOYSA-N [1-hydroxy-3-(2-methyl-1,3-thiazol-5-yl)-1-phosphonopropyl]phosphonic acid Chemical compound CC1=NC=C(CCC(O)(P(O)(O)=O)P(O)(O)=O)S1 WFFDAVXCSRTNQZ-UHFFFAOYSA-N 0.000 description 1
- LUNWWKRDWXXNES-UHFFFAOYSA-N [1-hydroxy-3-[1-[(3-nitrophenyl)methyl]triazol-4-yl]-1-phosphonopropyl]phosphonic acid Chemical compound N1=NC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=CN1CC1=CC=CC([N+]([O-])=O)=C1 LUNWWKRDWXXNES-UHFFFAOYSA-N 0.000 description 1
- QFVIUXMJTJOTOK-UHFFFAOYSA-N [1-hydroxy-4-(1h-imidazol-5-yl)-1-phosphonobutyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCCC1=CNC=N1 QFVIUXMJTJOTOK-UHFFFAOYSA-N 0.000 description 1
- MBMXXJSGVABQRP-UHFFFAOYSA-N [1-hydroxy-5-(1-methylbenzimidazol-2-yl)-1-phosphonopentyl]phosphonic acid Chemical compound C1=CC=C2N(C)C(CCCCC(O)(P(O)(O)=O)P(O)(O)=O)=NC2=C1 MBMXXJSGVABQRP-UHFFFAOYSA-N 0.000 description 1
- QBUASVKBKWDAEG-UHFFFAOYSA-N [1-hydroxy-5-(1-methyltriazol-4-yl)-1-phosphonopentyl]phosphonic acid Chemical compound CN1C=C(CCCCC(O)(P(O)(O)=O)P(O)(O)=O)N=N1 QBUASVKBKWDAEG-UHFFFAOYSA-N 0.000 description 1
- PQFZZQYIUCLTNC-UHFFFAOYSA-N [1-hydroxy-5-(6-methyl-1h-benzimidazol-5-yl)-1-phosphonopentyl]phosphonic acid Chemical compound C1=C(CCCCC(O)(P(O)(O)=O)P(O)(O)=O)C(C)=CC2=C1NC=N2 PQFZZQYIUCLTNC-UHFFFAOYSA-N 0.000 description 1
- SKHIUBBNQUOURQ-UHFFFAOYSA-N [3-(1-benzylimidazol-2-yl)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCC1=NC=CN1CC1=CC=CC=C1 SKHIUBBNQUOURQ-UHFFFAOYSA-N 0.000 description 1
- ILEPKWGFVLSTDX-UHFFFAOYSA-N [3-(1h-imidazol-5-yl)-1-phosphono-1-propanoyloxypropyl]phosphonic acid Chemical compound CCC(=O)OC(P(O)(O)=O)(P(O)(O)=O)CCC1=CNC=N1 ILEPKWGFVLSTDX-UHFFFAOYSA-N 0.000 description 1
- RCEIQYGVWKVXKA-UHFFFAOYSA-N [3-(1h-imidazol-5-yl)-1-phosphonopropyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)CCC1=CNC=N1 RCEIQYGVWKVXKA-UHFFFAOYSA-N 0.000 description 1
- CIXROXYKRFONOP-UHFFFAOYSA-N [3-(2,6-dimethyl-1h-benzimidazol-5-yl)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CC1=C(CCC(O)(P(O)(O)=O)P(O)(O)=O)C=C2NC(C)=NC2=C1 CIXROXYKRFONOP-UHFFFAOYSA-N 0.000 description 1
- JMGJBPUNZAANMG-UHFFFAOYSA-N [3-(2-acetamido-1,3-thiazol-4-yl)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CC(=O)NC1=NC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=CS1 JMGJBPUNZAANMG-UHFFFAOYSA-N 0.000 description 1
- LFUNUKCANFSWPV-UHFFFAOYSA-N [3-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound NC1=NC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=CS1 LFUNUKCANFSWPV-UHFFFAOYSA-N 0.000 description 1
- BHFFBFRXLSSMKA-UHFFFAOYSA-N [3-(3h-benzimidazol-5-yl)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCC1=CC=C2N=CNC2=C1 BHFFBFRXLSSMKA-UHFFFAOYSA-N 0.000 description 1
- DEZKXJGQEAQXCY-UHFFFAOYSA-N [3-(4,5-dimethyl-1,3-oxazol-2-yl)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CC=1N=C(CCC(O)(P(O)(O)=O)P(O)(O)=O)OC=1C DEZKXJGQEAQXCY-UHFFFAOYSA-N 0.000 description 1
- NXUGZLZRWHNTCE-UHFFFAOYSA-N [3-(5-amino-1-methyltriazol-4-yl)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN1N=NC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=C1N NXUGZLZRWHNTCE-UHFFFAOYSA-N 0.000 description 1
- LVJLSIXWAUDRDP-UHFFFAOYSA-N [3-[1-[(3-aminophenyl)methyl]triazol-4-yl]-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound NC1=CC=CC(CN2N=NC(CCC(O)(P(O)(O)=O)P(O)(O)=O)=C2)=C1 LVJLSIXWAUDRDP-UHFFFAOYSA-N 0.000 description 1
- NERBLRSCYKALBT-UHFFFAOYSA-N [4-(1-benzyltriazol-4-yl)-1-hydroxy-1-phosphonobutyl]phosphonic acid Chemical compound N1=NC(CCCC(O)(P(O)(O)=O)P(O)(O)=O)=CN1CC1=CC=CC=C1 NERBLRSCYKALBT-UHFFFAOYSA-N 0.000 description 1
- ZULQSUNVPVZLNC-UHFFFAOYSA-N [4-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-1-phosphonobutyl]phosphonic acid Chemical compound NC1=NC(CCCC(O)(P(O)(O)=O)P(O)(O)=O)=CS1 ZULQSUNVPVZLNC-UHFFFAOYSA-N 0.000 description 1
- DHNIDMIKDKLBSR-UHFFFAOYSA-N [4-(4,5-dimethyl-1,3-oxazol-2-yl)-1-hydroxy-1-phosphonobutyl]phosphonic acid Chemical compound CC=1N=C(CCCC(O)(P(O)(O)=O)P(O)(O)=O)OC=1C DHNIDMIKDKLBSR-UHFFFAOYSA-N 0.000 description 1
- CPKIOAFPNALBMS-UHFFFAOYSA-N [5-(1-benzyltriazol-4-yl)-1-hydroxy-1-phosphonopenta-2,4-dienyl]phosphonic acid Chemical compound N1=NC(C=CC=CC(O)(P(O)(O)=O)P(O)(O)=O)=CN1CC1=CC=CC=C1 CPKIOAFPNALBMS-UHFFFAOYSA-N 0.000 description 1
- DFTMPXZLIOHLBW-UHFFFAOYSA-N [5-(1-benzyltriazol-4-yl)-1-hydroxy-1-phosphonopentyl]phosphonic acid Chemical compound N1=NC(CCCCC(O)(P(O)(O)=O)P(O)(O)=O)=CN1CC1=CC=CC=C1 DFTMPXZLIOHLBW-UHFFFAOYSA-N 0.000 description 1
- VDZPFLQAHZCJPO-UHFFFAOYSA-N [5-(1-benzyltriazol-4-yl)-1-phosphono-1-propanoyloxypentyl]phosphonic acid Chemical compound N1=NC(CCCCC(OC(=O)CC)(P(O)(O)=O)P(O)(O)=O)=CN1CC1=CC=CC=C1 VDZPFLQAHZCJPO-UHFFFAOYSA-N 0.000 description 1
- ARKIUBVPYUNTIT-UHFFFAOYSA-N [5-(1h-benzimidazol-2-yl)-1-hydroxy-1-phosphonopentyl]phosphonic acid Chemical compound C1=CC=C2NC(CCCCC(O)(P(O)(O)=O)P(O)(O)=O)=NC2=C1 ARKIUBVPYUNTIT-UHFFFAOYSA-N 0.000 description 1
- YQNCYFIUVFSDKZ-UHFFFAOYSA-N [5-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-1-phosphonopentyl]phosphonic acid Chemical compound NC1=NC(CCCCC(O)(P(O)(O)=O)P(O)(O)=O)=CS1 YQNCYFIUVFSDKZ-UHFFFAOYSA-N 0.000 description 1
- RKPSPTSZJYOUNC-UHFFFAOYSA-N [5-(2-amino-4-methyl-1,3-thiazol-5-yl)-1-hydroxy-1-phosphonopentyl]phosphonic acid Chemical compound CC=1N=C(N)SC=1CCCCC(O)(P(O)(O)=O)P(O)(O)=O RKPSPTSZJYOUNC-UHFFFAOYSA-N 0.000 description 1
- QVGJLZCFVROWTL-UHFFFAOYSA-N [5-(2-benzyl-1,3-oxazol-4-yl)-1-hydroxy-1-phosphonopentyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCCCC1=COC(CC=2C=CC=CC=2)=N1 QVGJLZCFVROWTL-UHFFFAOYSA-N 0.000 description 1
- RSENFOBBLBEZGC-UHFFFAOYSA-N [5-(3h-benzimidazol-5-yl)-1-hydroxy-1-phosphonopentyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCCCC1=CC=C2N=CNC2=C1 RSENFOBBLBEZGC-UHFFFAOYSA-N 0.000 description 1
- SFFIKEAOFRTXAG-UHFFFAOYSA-N [5-(4,5-dimethyl-1,3-oxazol-2-yl)-1-hydroxy-1-phosphonopentyl]phosphonic acid Chemical compound CC=1N=C(CCCCC(O)(P(O)(O)=O)P(O)(O)=O)OC=1C SFFIKEAOFRTXAG-UHFFFAOYSA-N 0.000 description 1
- YRKNTCACADBOBB-UHFFFAOYSA-N [5-(5-amino-1-benzyltriazol-4-yl)-1-hydroxy-1-phosphonopentyl]phosphonic acid Chemical compound NC1=C(CCCCC(O)(P(O)(O)=O)P(O)(O)=O)N=NN1CC1=CC=CC=C1 YRKNTCACADBOBB-UHFFFAOYSA-N 0.000 description 1
- HEXVFIWZPOYPIY-UHFFFAOYSA-N [5-(5-amino-2h-triazol-4-yl)-1-hydroxy-1-phosphonopentyl]phosphonic acid Chemical compound NC=1NN=NC=1CCCCC(O)(P(O)(O)=O)P(O)(O)=O HEXVFIWZPOYPIY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000007941 heterotopic ossification Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Non-Portable Lighting Devices Or Systems Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3428524A DE3428524A1 (de) | 1984-08-02 | 1984-08-02 | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS257277B2 true CS257277B2 (en) | 1988-04-15 |
Family
ID=6242211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS855580A CS257277B2 (en) | 1984-08-02 | 1985-07-31 | Production method of diphosphone acid derivatives |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US4687767A (da) |
| EP (1) | EP0170228B1 (da) |
| JP (1) | JPS6143197A (da) |
| AT (1) | ATE39489T1 (da) |
| AU (1) | AU553419B2 (da) |
| CA (1) | CA1264326A (da) |
| CS (1) | CS257277B2 (da) |
| DD (1) | DD236533A5 (da) |
| DE (2) | DE3428524A1 (da) |
| DK (1) | DK345285A (da) |
| ES (1) | ES8606876A1 (da) |
| FI (1) | FI78915C (da) |
| GR (1) | GR851881B (da) |
| HU (1) | HU196419B (da) |
| IL (1) | IL75971A (da) |
| SU (1) | SU1475487A3 (da) |
| ZA (1) | ZA855760B (da) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3428524A1 (de) * | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| PH27078A (en) * | 1984-12-21 | 1993-02-01 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonates |
| IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| US5641762A (en) * | 1985-05-02 | 1997-06-24 | Research Corporation Technologies, Inc. | Bone targeted inhibitors of carbonic anhydrase |
| DE3540150A1 (de) * | 1985-11-13 | 1987-05-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4902679A (en) * | 1985-12-13 | 1990-02-20 | Norwich Eaton Pharmaceuticals, Inc. | Methods of treating diseases with certain geminal diphosphonates |
| DE3770982D1 (de) * | 1986-04-24 | 1991-08-01 | Fujisawa Pharmaceutical Co | Diphosphonsaeure-verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel. |
| DE3626058A1 (de) * | 1986-08-01 | 1988-02-11 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US5057505A (en) * | 1986-11-21 | 1991-10-15 | Ciba-Geigy Corporation | Substituted aminomethanediphosphonic acids and use in medicaments |
| ATE64397T1 (de) * | 1986-11-21 | 1991-06-15 | Ciba Geigy Ag | Aromatisch substituierte azacycloalkylalkandiphosphons|uren. |
| DE3776880D1 (de) * | 1986-11-21 | 1992-04-02 | Ciba Geigy Ag | Neue substituierte alkandiphosphonsaeuren. |
| DE3640938A1 (de) * | 1986-11-29 | 1988-06-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel |
| US5071840A (en) * | 1986-12-19 | 1991-12-10 | Norwich Eaton Pharmaceuticals, Inc. | Certain heterocyclic substituted diphosphonate compounds pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism |
| US4868164A (en) * | 1986-12-19 | 1989-09-19 | Norwich Eaton Pharmaceuticals, Inc. | Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| US4939265A (en) * | 1987-02-25 | 1990-07-03 | Bristol-Myers Company | Intermediates and process for the preparation of antihypercholesterolemic tetrazole compounds |
| DK126888A (da) * | 1987-03-10 | 1988-09-11 | Yamanouchi Pharma Co Ltd | Bisphosphonsyrederivater og terapeutiske praeparater indeholdende disse forbindelser |
| KR880011136A (ko) * | 1987-03-11 | 1988-10-26 | 모리오까 시게오 | 아졸- 아미노메틸렌 비스포스폰산 유도체 |
| US4963681A (en) * | 1987-07-06 | 1990-10-16 | Norwich Eaton Pharmaceuticals, Inc. | Process for synthesis of aminomethylene phosphonoalkylphosphinates |
| IL86951A (en) * | 1987-07-06 | 1996-07-23 | Procter & Gamble Pharma | Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them |
| EP0317505A1 (de) * | 1987-11-13 | 1989-05-24 | Ciba-Geigy Ag | Neue Azacycloalkylalkandiphosphonsäuren |
| US5110807A (en) * | 1988-12-01 | 1992-05-05 | Ciba-Geigy Corporation | Araliphatylaminoalkanediphosphonic acids |
| US5190930A (en) * | 1987-12-11 | 1993-03-02 | Ciba-Geigy Corporation | Araliphatylaminoalkanediphosphonic acids |
| DE3817956A1 (de) * | 1988-05-27 | 1989-12-07 | Hoechst Ag | Verfahren zur herstellung phosphorhaltiger l-aminosaeuren sowie ihrer ester und n-derivate |
| DE3822650A1 (de) * | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4990503A (en) * | 1988-08-12 | 1991-02-05 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclic bisphosphonic acid derivatives |
| TW198039B (da) * | 1988-11-28 | 1993-01-11 | Ciba Geigy Ag | |
| DE3917153A1 (de) * | 1989-05-26 | 1990-11-29 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| MX21452A (es) * | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | Preparaciones farmaceuticas que se administran en forma topica. |
| US5139786A (en) * | 1989-07-07 | 1992-08-18 | Ciba-Geigy Corporation | Topical formulations |
| AU7165791A (en) * | 1990-01-12 | 1991-08-05 | Rhone-Poulenc Rorer International (Holdings) Inc. | 1-azetidyl and 1-hexamethylenimine alkyl or aryl bisphosphonic acids and their use as pharmacological agents |
| US5204334A (en) * | 1990-10-18 | 1993-04-20 | Ciba-Geigy Corporation | Benzoheterocyclylalkylaminoalkanediphosphonic acids, compositions thereof, and use thereof in the treatment of calcium metabolism disorders |
| ATE168379T1 (de) * | 1992-05-29 | 1998-08-15 | Procter & Gamble Pharma | Quaternare stickstoff-enthaltende phosphonat- verbindungen zur behandlung abnormalen calzium und phosphat-metabolismus sowie zahnsteinbildung |
| PL175046B1 (pl) * | 1992-05-29 | 1998-10-30 | Procter & Gamble Pharma | Nowe tio-podstawione, zawierające azot heterocykliczne związki fosfonianowe |
| US5391743A (en) * | 1992-05-29 | 1995-02-21 | Procter & Gamble Pharmaceuticals, Inc. | Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque |
| US5763611A (en) * | 1992-05-29 | 1998-06-09 | The Procter & Gamble Company | Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| US5753634A (en) * | 1992-05-29 | 1998-05-19 | The Procter & Gamble Company | Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism |
| PL175475B1 (pl) * | 1992-05-29 | 1999-01-29 | Procter & Gamble Pharma | Nowe zawierające siarkę związki fosfonianowe |
| JPH07508279A (ja) * | 1992-06-30 | 1995-09-14 | プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド | ホスホネート類及びｎｓａｉｄを含有した関節炎の治療用組成物 |
| DE4228552A1 (de) * | 1992-08-27 | 1994-03-03 | Boehringer Mannheim Gmbh | Diphosphonsäuren und deren Salze enthaltende Arzneimittel |
| AU670337B2 (en) | 1992-11-30 | 1996-07-11 | Novartis Ag | Use of certain methanebisphosphonic acid derivatives in fracture healing |
| JPH06298779A (ja) * | 1993-04-15 | 1994-10-25 | Hoechst Japan Ltd | ヘテロ環イミノビスメチレンビスホスホン酸誘導体 |
| GB9324143D0 (en) * | 1993-11-24 | 1994-01-12 | Schering Agrochemicals Ltd | Triazole phosphonate pesticides |
| WO1997012619A1 (en) * | 1995-09-29 | 1997-04-10 | Novartis Ag | Method of treating the navicular disease in horses |
| EP1246829A1 (en) * | 1999-12-17 | 2002-10-09 | Ariad Pharmaceuticals, Inc. | Novel heterocycles |
| US7115589B2 (en) | 1999-12-17 | 2006-10-03 | Ariad Pharmaceuticals, Inc. | Purine derivatives |
| AU2583901A (en) * | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| US6677320B2 (en) | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| PE20011061A1 (es) * | 2000-02-01 | 2001-11-20 | Procter & Gamble | Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato |
| CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
| PT1506041E (pt) | 2002-05-10 | 2007-12-28 | Hoffmann La Roche | Ácido ibandrónico para o tratamento e a prevenção da osteoporose |
| JP4485117B2 (ja) * | 2002-06-27 | 2010-06-16 | 日東電工株式会社 | 保護剥離用フィルム |
| ATE345790T1 (de) * | 2002-07-30 | 2006-12-15 | Novartis Pharma Gmbh | Kombination von einem aromatasehemmer mit einem bisphosphonat |
| TW200413381A (en) | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
| US20040206932A1 (en) | 2002-12-30 | 2004-10-21 | Abuelyaman Ahmed S. | Compositions including polymerizable bisphosphonic acids and methods |
| HUP0300227A2 (hu) * | 2003-01-28 | 2004-09-28 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására |
| US20050065171A1 (en) * | 2003-06-25 | 2005-03-24 | Shakespeare William C. | Substituted purine derivatives |
| JP5001006B2 (ja) | 2003-08-12 | 2012-08-15 | スリーエム イノベイティブ プロパティズ カンパニー | 自己エッチング性歯科用組成物および方法 |
| US20050119230A1 (en) * | 2003-09-18 | 2005-06-02 | Alexandra Glausch | Pharmaceutical products comprising bisphosphonated |
| CN101018534B (zh) | 2004-07-08 | 2012-07-04 | 3M创新有限公司 | 牙科的方法，组合物，和包括酸敏感染料的试剂盒 |
| US8722760B2 (en) | 2004-08-11 | 2014-05-13 | 3M Innovative Properties Company | Self-adhesive compositions including a plurality of acidic compounds |
| EP2101716A2 (en) * | 2006-12-13 | 2009-09-23 | 3M Innovative Properties Company | Methods of using a dental composition having an acidic component and a photobleachable dye |
| WO2008074145A1 (en) * | 2006-12-20 | 2008-06-26 | Genpharm Ulc | Pharmaceutical composition comprising a hot-melt granulated lubricant |
| US20100179110A1 (en) * | 2006-12-20 | 2010-07-15 | Mostafa Akbarieh | Composition Containing a Bisphosphonic Acid in Combination with Vitamin D |
| EP2136814A4 (en) * | 2007-03-21 | 2012-05-30 | Univ Duke | MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE |
| AU2009334889A1 (en) * | 2008-12-23 | 2011-06-30 | Novartis Ag | Phenylalkyl-imidazole-bisphosphonate compounds |
| HUE025737T2 (en) | 2009-09-01 | 2016-05-30 | Univ Duke | Bisphosphonate compositions and methods for treating heart failure |
| JP6261512B2 (ja) | 2011-11-16 | 2018-01-17 | デューク ユニバーシティ | 心機能障害を治療及び／又は低減するためのビスホスホネート組成物並びに方法 |
| PL407922A1 (pl) | 2014-04-16 | 2015-10-26 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Nowe bisfosfoniany i ich zastosowanie |
| WO2019076269A1 (zh) | 2017-10-16 | 2019-04-25 | 清华大学 | 甲羟戊酸通路抑制剂及其药物组合物 |
| USD958651S1 (en) | 2020-08-11 | 2022-07-26 | Bocks Inc. | Liquid soap dispenser carton |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH9776A (en) * | 1967-12-11 | 1976-03-17 | M Francis | Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use |
| DE3203308A1 (de) * | 1982-01-27 | 1983-07-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate |
| EP0084822B1 (de) * | 1982-01-27 | 1986-01-08 | Schering Aktiengesellschaft | Diphosphonsäure-Derivate und diese enthaltende pharmazeutische Präparate |
| DE3203309A1 (de) * | 1982-01-27 | 1983-07-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate |
| DE3365492D1 (en) * | 1982-01-27 | 1986-10-02 | Schering Ag | Diphosphonic acid derivatives and pharmaceutical preparations containing them |
| DE3428524A1 (de) * | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
-
1984
- 1984-08-02 DE DE3428524A patent/DE3428524A1/de not_active Withdrawn
-
1985
- 1985-07-24 CA CA000487443A patent/CA1264326A/en not_active Expired - Lifetime
- 1985-07-26 DE DE8585109432T patent/DE3567023D1/de not_active Expired
- 1985-07-26 US US06/759,608 patent/US4687767A/en not_active Expired - Lifetime
- 1985-07-26 AT AT85109432T patent/ATE39489T1/de active
- 1985-07-26 EP EP85109432A patent/EP0170228B1/de not_active Expired
- 1985-07-30 DD DD85279140A patent/DD236533A5/de not_active IP Right Cessation
- 1985-07-30 DK DK345285A patent/DK345285A/da not_active Application Discontinuation
- 1985-07-30 IL IL75971A patent/IL75971A/xx not_active IP Right Cessation
- 1985-07-31 ZA ZA855760A patent/ZA855760B/xx unknown
- 1985-07-31 GR GR851881A patent/GR851881B/el unknown
- 1985-07-31 CS CS855580A patent/CS257277B2/cs not_active IP Right Cessation
- 1985-08-01 AU AU45686/85A patent/AU553419B2/en not_active Ceased
- 1985-08-01 FI FI852980A patent/FI78915C/fi not_active IP Right Cessation
- 1985-08-01 SU SU853935742A patent/SU1475487A3/ru active
- 1985-08-01 HU HU852957A patent/HU196419B/hu not_active IP Right Cessation
- 1985-08-02 JP JP60169944A patent/JPS6143197A/ja active Pending
- 1985-08-02 ES ES545842A patent/ES8606876A1/es not_active Expired
-
1987
- 1987-07-23 US US07/076,706 patent/US4784993A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IL75971A0 (en) | 1985-12-31 |
| IL75971A (en) | 1989-05-15 |
| DK345285A (da) | 1986-02-03 |
| DD236533A5 (de) | 1986-06-11 |
| FI852980A0 (fi) | 1985-08-01 |
| SU1475487A3 (ru) | 1989-04-23 |
| DK345285D0 (da) | 1985-07-30 |
| HU196419B (en) | 1988-11-28 |
| AU553419B2 (en) | 1986-07-17 |
| FI852980L (fi) | 1986-02-03 |
| CA1264326A (en) | 1990-01-09 |
| US4687767A (en) | 1987-08-18 |
| AU4568685A (en) | 1986-02-06 |
| HUT38364A (en) | 1986-05-28 |
| DE3428524A1 (de) | 1986-02-13 |
| US4784993A (en) | 1988-11-15 |
| ATE39489T1 (de) | 1989-01-15 |
| EP0170228B1 (de) | 1988-12-28 |
| DE3567023D1 (en) | 1989-02-02 |
| FI78915B (fi) | 1989-06-30 |
| ES8606876A1 (es) | 1986-05-16 |
| ZA855760B (en) | 1986-04-30 |
| GR851881B (da) | 1985-12-02 |
| ES545842A0 (es) | 1986-05-16 |
| EP0170228A1 (de) | 1986-02-05 |
| JPS6143197A (ja) | 1986-03-01 |
| FI78915C (fi) | 1989-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS257277B2 (en) | Production method of diphosphone acid derivatives | |
| FI87223B (fi) | Foerfarande foer framstaellning av nya farmakologiskt aktiva alkyldifosfonsyraderivat. | |
| JP3224817B2 (ja) | 新規なメチレンビスホスホン酸誘導体 | |
| JPS5942395A (ja) | メチレン−ジホスホン酸から誘導された炎症抑制性生成物およびその製造方法 | |
| NO841106L (no) | Fremgangsmaate for fremstilling av kondenserte imidazolderivater | |
| JPS63150291A (ja) | 置換アルカンジホスホン酸 | |
| KR100233986B1 (ko) | 신규한 메틸렌비 스포스폰산 유도체 | |
| DE69811930T2 (de) | Tricyclische triazolobenzazepinderivate, verfahren zu ihrer herstellung und antiallergische mittel | |
| NZ253526A (en) | Thio-substituted heterocyclic phosphonate derivatives and medicaments | |
| US5206253A (en) | Disphosphonic acid derivatives, processes for their production and pharmaceutical preparations containing these compounds | |
| HU202880B (en) | Process for producing araliphatic aminoalkane diphosphonic acids and pharmaceutical compositions comprising such compounds | |
| HU201087B (en) | Process for producing substituted aminomethane diphosphonic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MK4A | Patent expired |
Effective date: 20000731 |